Grant: Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
Sunnybrook Research Institute (Toronto, Ontario)
$20,000.00
Pro-Resolving Inflammatory Mediators in Neurovascular Gains in Aerobic Training; a phase 2, double-blind, randomized placebo-controlled trial (PRIMiNG-AT2)
FY 2022-23
Summary
As people age, the risk of developing dementia increases, especially in those with inflammatory conditions like coronary artery disease and type 2 diabetes mellitus. These conditions can lead to small vessel disease in the brain, which contributes to cognitive decline and dementia risk. Currently, there is no therapy approved to protect the brain's small vessels.
Previous studies have shown that exercise can improve brain blood vessel function and cognitive performance, but the effects are not consistent in people with coronary artery disease or type 2 diabetes mellitus. Exercise generates epoxide metabolites from dietary fatty acids that support cerebral blood flow and resolution of inflammation, but as people age, soluble epoxide hydrolase (sEH) breaks down these epoxides into toxic products that may harm the small vessels of the brain.
The aim of this Phase 2 trial is to determine if an inhibitor of sEH called EC5026 can protect the small vessels of the brain for both men and women with coronary artery disease and/or type 2 diabetes mellitus, and restore the brain benefit of physical exercise training. The trial will randomly assign 160 patients to EC5026 or placebo daily for 24 weeks. The primary outcome will be cognitive performance. The secondary outcome will be blood flow to the brain. The study will also monitor blood vessel function throughout the body over time to determine how the drug works, and examine blood tests taken before the drug is given to determine if certain people may benefit from the drug more than others.
The team, spanning multiple countries and institutions, includes pharmacologists, neurologists, endocrinologists, kinesiologists, imaging scientists, other medical specialists, and a person who previously completed the exercise program. The trial will be the first to target the small vessels in the brain to boost the benefits of exercise. The results will inform further trials, and how to improve exercise training to prevent dementia.
Department
Program
Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
485524
Name
Swardfager Walter L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Team Grant : Intervention Trial in Inflammation for Chronic Conditions
Projecttitle
Pro-Resolving Inflammatory Mediators in Neurovascular Gains in Aerobic Training; a phase 2, double-blind, randomized placebo-controlled trial (PRIMiNG-AT2)
Programtype2
Operating Grants
Orgnameinp2
Sunnybrook Research Institute (Toronto, Ontario)
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
Keyworddelim
Aging; Cerebral Small Vessels; Coronary Artery Disease; Diabetes; Inflammation; Physical Activity
Abstract
As people age, the risk of developing dementia increases, especially in those with inflammatory conditions like coronary artery disease and type 2 diabetes mellitus. These conditions can lead to small vessel disease in the brain, which contributes to cognitive decline and dementia risk. Currently, there is no therapy approved to protect the brain's small vessels.
Previous studies have shown that exercise can improve brain blood vessel function and cognitive performance, but the effects are not consistent in people with coronary artery disease or type 2 diabetes mellitus. Exercise generates epoxide metabolites from dietary fatty acids that support cerebral blood flow and resolution of inflammation, but as people age, soluble epoxide hydrolase (sEH) breaks down these epoxides into toxic products that may harm the small vessels of the brain.
The aim of this Phase 2 trial is to determine if an inhibitor of sEH called EC5026 can protect the small vessels of the brain for both men and women with coronary artery disease and/or type 2 diabetes mellitus, and restore the brain benefit of physical exercise training. The trial will randomly assign 160 patients to EC5026 or placebo daily for 24 weeks. The primary outcome will be cognitive performance. The secondary outcome will be blood flow to the brain. The study will also monitor blood vessel function throughout the body over time to determine how the drug works, and examine blood tests taken before the drug is given to determine if certain people may benefit from the drug more than others.
The team, spanning multiple countries and institutions, includes pharmacologists, neurologists, endocrinologists, kinesiologists, imaging scientists, other medical specialists, and a person who previously completed the exercise program. The trial will be the first to target the small vessels in the brain to boost the benefits of exercise. The results will inform further trials, and how to improve exercise training to prevent dementia.
Competitiondate
202303
Approvedterm2
1 yr 0 mth
Pinamesdelim
Swardfager, Walter L; Lanctôt, Krista L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $20,000~ $0~